journal
MENU ▼
Read by QxMD icon Read
search

Seminars in Oncology

journal
https://www.readbyqxmd.com/read/28395769/commentary-on-screening-for-lung-cancer-by-sateia-et-al
#1
EDITORIAL
Paul F Pinsky
No abstract text is available yet for this article.
February 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28395768/what-constitutes-an-unmet-medical-need-in-oncology-an-empirical-evaluation-of-author-usage-in-the-biomedical-literature
#2
Eric Lu, Joseph Shatzel, Florence Shin, Vinay Prasad
The phrase "unmet medical need" has important regulatory implications, but there is no empirical analysis of its real world usage. We sought to determine the annual US incidence, 5-year survival, and number of National Comprehensive Cancer Network (NCCN)-recommended regimens for indications described in the literature as an "unmet medical need." We queried Google Scholar to identify publications where authors used the phrase "unmet medical need" to refer to a specific cancer indication. For each indication, we investigated the annual US incidence, 5-year survival, and number of NCCN recommended regimens...
February 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28395767/screening-for-lung-cancer
#3
REVIEW
Heather F Sateia, Youngjee Choi, Rosalyn W Stewart, Kimberly S Peairs
This review will comprise a general overview of the epidemiology of lung cancer, as well as lung cancer risk factors, screening modalities, current guideline recommendations for screening, and our approach to lung cancer screening.
February 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28395766/commentary-on-screening-for-breast-cancer-by-peairs-et-al
#4
EDITORIAL
Pamela M Marcus, Danielle D Durham
No abstract text is available yet for this article.
February 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28395765/screening-for-breast-cancer
#5
REVIEW
Kimberly S Peairs, Youngjee Choi, Rosalyn W Stewart, Heather F Sateia
This review will give a general overview of the impact of breast cancer, as well as breast cancer risk factors, identification of high-risk groups, screening modalities, and guidelines for screening average-risk and high-risk individuals, including a case discussion of the primary care provider's approach to screening.
February 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28395764/commentary-prostate-cancer-screening-a-long-run-for-a-short-slide
#6
EDITORIAL
Howard L Parnes
No abstract text is available yet for this article.
February 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28395763/screening-for-prostate-cancer
#7
REVIEW
Rosalyn W Stewart, Sergio Lizama, Kimberly Peairs, Heather F Sateia, Youngjee Choi
This review comprises a general overview of the impact and risk factors for prostate cancer. Evidenced-based professional society prostate cancer screening guideline recommendations are reviewed, and our approach to a case is presented.
February 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28395762/commentary-choosing-how-to-screen-for-colorectal-cancer
#8
EDITORIAL
Alfred I Neugut, Benjamin Lebwohl
No abstract text is available yet for this article.
February 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28395761/screening-for-colorectal-cancer
#9
REVIEW
Youngjee Choi, Heather F Sateia, Kimberly S Peairs, Rosalyn W Stewart
This review will comprise a general overview of colorectal cancer (CRC) screening. We will cover the impact of CRC, CRC risk factors, screening modalities, and guideline recommendations for screening in average-risk and high-risk individuals. Based on this data, we will summarize our approach to CRC screening.
February 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28395760/characterization-of-outcomes-in-patients-with-metastatic-non-small-cell-lung-cancer-treated-with-programmed-cell-death-protein-1-inhibitors-past-recist-version-1-1-defined-disease-progression-in-clinical-trials
#10
Dickran Kazandjian, Patricia Keegan, Daniel L Suzman, Richard Pazdur, Gideon M Blumenthal
Based on anecdotal cases of clinically important decreases in tumor size following initial evidence of disease progression when treating patients with anti-PD-1 therapies, investigators have conducted clinical trials in patients with metastatic non-small lung cancer (mNSCLC) receiving anti-PD-1 therapy allowing for treatment past RECIST-defined disease progression (TPP). We describe the findings of a pooled analysis of three clinical trials submitted to the US Food and Drug administration (FDA) where treatment of patients with mNSCLC permitted TPP in terms of reduction in the sum of target lesions following initial RECIST-defined progression...
February 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28395759/a-multicenter-phase-ii-study-of-personalized-folfiri-cetuximab-for-safe-dose-intensification
#11
Michèle Boisdron-Celle, Jean Philippe Metges, Olivier Capitain, Antoine Adenis, Jean Luc Raoul, Thierry Lecomte, You Heng Lam, Roger Faroux, Claude Masliah, Anne Lise Poirier, Virginie Berger, Alain Morel, Erick Gamelin
We conducted a multicenter proof of concept phase II trial in patients with advanced colorectal cancer receiving FOLFIRI-cetuximab regimens to explore individual drug tailoring using pharmacogenetics and pharmacokinetics (PK) monitoring. Patients were stratified by their pharmacogenetic/phenotypic status: the irinotecan dose was adjusted according to the number of TA tandem repeats in the UGT1A1 promoter, while the 5-fluorouracil (5-FU) dose was initially adjusted according to dihydropyrimidine dehydrogenase (DPD) activity at initial screening (5-FU(ODPM Tox)) followed by PK-guided dose optimization (5-FU(ODPM Protocol))...
February 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28395758/prevention-of-5-fluorouracil-induced-early-severe-toxicity-by-pre-therapeutic-dihydropyrimidine-dehydrogenase-deficiency-screening-assessment-of-a-multiparametric-approach
#12
Michele Boisdron-Celle, Olivier Capitain, Roger Faroux, Christophe Borg, Jean Philippe Metges, Marie Pierre Galais, Mehdi Kaassis, Jaafar Bennouna, Karine Bouhier-Leporrier, Eric Francois, Isabelle Baumgaertner, Véronique Guerin-Meyer, Oana Cojocarasu, Celia Roemer-Becuwe, Claire Stampfli, Ludovic Rosenfeld, Thierry Lecompte, Virginie Berger, Alain Morel, Erick Gamelin
5-Fluorouracil (5-FU)-based treatments can lead to early-onset severe (4%-5%) even fatal (0.3%) toxicities in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. This multicenter prospective cohort study aimed to assess the clinical benefit of pretherapeutic screening for DPD deficiency using a multiparametric approach. Two parallel cohorts of patients treated with 5-FU-based chemotherapy for colorectal carcinoma were compared in a prospective nonrandomized study. In arm A, patients had DPD deficiency screening before treatment, whereas in arm B no pretherapy screening was performed...
February 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28395757/pseudo-progressing-to-an-unmet-need
#13
EDITORIAL
Tito Fojo
No abstract text is available yet for this article.
February 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28061995/optimal-treatment-strategies-in-myeloma-an-argument-against-maintenance-therapy-after-autologous-stem-cell-transplantation
#14
REVIEW
Joshua Richter, Noa Biran, David Vesole, David Siegel
Despite continuing advancements in novel therapeutics for multiple myeloma (MM), high-dose therapy with autologous stem cell rescue continues to represent the standard approach to treat transplant-eligible, newly diagnosed patients. As the disease remains essentially incurable, and median progression-free survival (PFS) times after autologous transplant are measured in years and not decades, attempts to improve outcomes in the post-transplant setting have been extensive and commonly focused on a "maintenance" approach...
December 2016: Seminars in Oncology
https://www.readbyqxmd.com/read/28061994/recommend-maintenance-therapy-with-lenalidomide-in-multiple-myeloma
#15
REVIEW
Elisabet E Manasanch
Thalidomide was the first immunomodulatory drug used as maintenance after autologous stem cell transplant (ASCT) in multiple myeloma (MM). This showed improved progression-free survival (PFS) and in some cases, overall survival (OS). Despite this, use of thalidomide was limited due to toxicity and high rates of therapy discontinuation. Lenalidomide, an analog of thalidomide, had a more favorable toxicity profile making its use in maintenance a potential approach. The use of lenalidomide as a maintenance therapy after ASCT in newly diagnosed MM patients has been investigated in four phase III randomized control studies...
December 2016: Seminars in Oncology
https://www.readbyqxmd.com/read/28061993/deferring-autologous-stem-cell-transplantation-for-consolidation-of-minimal-residual-disease-in-multiple-myeloma
#16
REVIEW
Marc Braunstein, Ruben Niesvizky
The expanding armamentarium of novel agents used in combination to treat multiple myeloma (MM) can induce clinical responses in most newly diagnosed patients, with encouraging outcomes observed in the relapsed/refractory setting. Highly sensitive techniques to detect minimal residual disease (MRD) are increasingly being employed to gauge the depth of response to modern anti-myeloma therapies and help guide therapeutic decisions. MM patients who have not achieved MRD-negativity, as assessed by one of several available assays, pose a therapeutic dilemma in terms of whether to proceed with high-dose therapy followed by autologous stem cell transplant (ASCT) versus administering additional cycles of chemotherapy...
December 2016: Seminars in Oncology
https://www.readbyqxmd.com/read/28061992/recommend-upfront-consolidation-with-high-dose-melphalan-and-autologous-stem-cell-support
#17
REVIEW
Gunjan L Shah, Sergio A Giralt
The overall goal of treatment for multiple myeloma (MM) is to prolong survival for as long as possible with the minimal treatment burden for each patient. Consolidation with upfront high-dose melphalan and autologous hematopoietic stem cell transplantation (ASCT) can prolong progression-free and overall survival by deepening response. It thereby can improve quality of life by allowing patients to have a time on maintenance therapy along with infrequent office visits, making it cost-effective in many situations...
December 2016: Seminars in Oncology
https://www.readbyqxmd.com/read/28061991/combination-therapy-for-fit-younger-and-older-newly-diagnosed-multiple-myeloma-patients-data-support-carfilzomib-lenalidomide-and-dexamethasone-independent-of-cytogenetic-risk-status
#18
REVIEW
Ola Landgren
In this invited paper, I was asked to critically review available literature and seek scientific and clinical evidence to argue in support of carfilzomib, lenalidomide, and dexamethasone (KRd) as the new default therapy for fit patients with a new diagnosis of multiple myeloma (MM). When performing the review of existing data and when writing this paper it became clear to me that both KRd and bortezomib, lenalidomide, and dexamethasone (RVd) are both recommended by established, well-respected expert guidelines...
December 2016: Seminars in Oncology
https://www.readbyqxmd.com/read/28061990/treatment-of-newly-diagnosed-myeloma-bortezomib-based-triplet
#19
REVIEW
Archana M Rajan, S Vincent Rajkumar
We review the options for the treatment of newly diagnosed myeloma in a patient who is a candidate for autologous stem cell transplantation (ASCT). Bortezomib, lenalidomide, dexamethasone (VRD) has been studied in two randomized trials as first-line therapy. In one of these trials, VRD demonstrated improved overall survival compared with lenalidomide plus dexamethasone (Rd). By contrast, phase III data with overall survival differences are not available for other bortezomib-containing regimens compared with modern lenalidomide-containing regimens...
December 2016: Seminars in Oncology
https://www.readbyqxmd.com/read/28061989/high-risk-smoldering-myeloma-perspective-on-watchful-monitoring
#20
REVIEW
Siyang Leng, Suzanne Lentzsch
In a 2008 paper, Dispenzieri and colleagues at the Mayo Clinic proposed a risk stratification system for patients with smoldering multiple myeloma (SMM) based on the presence of three risk factors: serum M-protein ≥3 g/dL, bone marrow plasma cell percentage ≥10%, and a free light chain (FLC) ratio (κ to λ) of either ≤0.125 or ≥8. The patient in this vignette has all three risk factors, classifying him as high-risk, with an associated median time to progression (TTP) of 1.9 years. This is significantly worse than a patient with intermediate-risk (median TTP 5...
December 2016: Seminars in Oncology
journal
journal
24921
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"